CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果

2014-05-05 秀荣医学论坛网

日本学者研究发现，MET过表达、BRAF 和PIK3CA突变是野生型KRAS转移性结直肠癌（mCRC）患者对抗EGFR MoAbs疗法反应性的一种有用的、新疗效预测指标；同时，他们的研究也提示，应用多种生物标记物对可能获益于抗EGFR疗法的患者进行选择比单独应用一种指标效果更好。论文2014年4月1日在线发表于《癌症化疗与药理学》（Cancer Chemotherapy and Pharmacol

日本学者研究发现，MET过表达、BRAF 和PIK3CA突变是野生型KRAS转移性结直肠癌（mCRC）患者对抗EGFR MoAbs疗法反应性的一种有用的、新疗效预测指标；同时，他们的研究也提示，应用多种生物标记物对可能获益于抗EGFR疗法的患者进行选择比单独应用一种指标效果更好。论文2014年4月1日在线发表于《癌症化疗与药理学》（Cancer Chemotherapy and Pharmacology）杂志。

研究根据KRAS、BRAF和PIK3CA 的突变状态以及PTEN和MET的表达情况，对91例mCRC患者进行抗EGFR MoAb疗法的疗效进行了回顾性评估。

结果为，在野生型KRAS患者群中，BRAF突变或PIK3CA 突变的发生与患者疾病控制率(DCR)较低、无进展生存 (PFS) 期和总生存期较短相关。与MET正常表达的患者相比，MET过表达的患者也表现出较低的DCR和较短的PFS。在一个独立分析中，44例野生型KRAS肿瘤患者被分为两个亚组：一组是BRAF、PIK3CA和MET 三分子未发生异常的25例患者，另一组是上述三分子中至少一种发生异常的19例患者；与后亚组相比，前亚组患者接受抗EGFR治疗时DCR显著增高和PFS显著延长。

原始出处：

Kishiki T1, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Watanabe T, Sugiyama M.Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.Cancer Chemother Pharmacol. 2014 Apr;73(4):749-57. doi: 10.1007/s00280-014-2401-4. Epub 2014 Feb 6.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1827225, encodeId=c28c182e2259b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Aug 07 02:56:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958154, encodeId=56f8195815405, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 06 16:56:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082883, encodeId=2681208288380, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96106, encryptionId=2436961068e, topicName=野生型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 16 01:56:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642734, encodeId=421d1642e3417, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Mon Nov 10 23:56:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895722, encodeId=3b001895e2205, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 18 16:56:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368980, encodeId=206f13689801e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534230, encodeId=e15f1534230af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621221, encodeId=51d21621221b8, content=<a href='/topic/show?id=33fa55081fe' target=_blank style='color:#2F92EE;'>#抗EGFR疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55081, encryptionId=33fa55081fe, topicName=抗EGFR疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10020217711, createdName=guoyibin, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
2014-08-07 yxch36

#CRC#

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1827225, encodeId=c28c182e2259b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Aug 07 02:56:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958154, encodeId=56f8195815405, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 06 16:56:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082883, encodeId=2681208288380, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96106, encryptionId=2436961068e, topicName=野生型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 16 01:56:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642734, encodeId=421d1642e3417, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Mon Nov 10 23:56:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895722, encodeId=3b001895e2205, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 18 16:56:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368980, encodeId=206f13689801e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534230, encodeId=e15f1534230af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621221, encodeId=51d21621221b8, content=<a href='/topic/show?id=33fa55081fe' target=_blank style='color:#2F92EE;'>#抗EGFR疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55081, encryptionId=33fa55081fe, topicName=抗EGFR疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10020217711, createdName=guoyibin, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
2015-02-06 lq1767

#过表达#

51 0
[GetPortalCommentsPageByObjectIdResponse(id=1827225, encodeId=c28c182e2259b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Aug 07 02:56:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958154, encodeId=56f8195815405, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 06 16:56:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082883, encodeId=2681208288380, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96106, encryptionId=2436961068e, topicName=野生型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 16 01:56:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642734, encodeId=421d1642e3417, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Mon Nov 10 23:56:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895722, encodeId=3b001895e2205, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 18 16:56:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368980, encodeId=206f13689801e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534230, encodeId=e15f1534230af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621221, encodeId=51d21621221b8, content=<a href='/topic/show?id=33fa55081fe' target=_blank style='color:#2F92EE;'>#抗EGFR疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55081, encryptionId=33fa55081fe, topicName=抗EGFR疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10020217711, createdName=guoyibin, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
2015-03-16 ms5106640509429053

#野生型#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1827225, encodeId=c28c182e2259b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Aug 07 02:56:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958154, encodeId=56f8195815405, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 06 16:56:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082883, encodeId=2681208288380, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96106, encryptionId=2436961068e, topicName=野生型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 16 01:56:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642734, encodeId=421d1642e3417, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Mon Nov 10 23:56:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895722, encodeId=3b001895e2205, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 18 16:56:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368980, encodeId=206f13689801e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534230, encodeId=e15f1534230af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621221, encodeId=51d21621221b8, content=<a href='/topic/show?id=33fa55081fe' target=_blank style='color:#2F92EE;'>#抗EGFR疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55081, encryptionId=33fa55081fe, topicName=抗EGFR疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10020217711, createdName=guoyibin, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
2014-11-10 LShY0906_98743851

#mCRC#

70 0
[GetPortalCommentsPageByObjectIdResponse(id=1827225, encodeId=c28c182e2259b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Aug 07 02:56:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958154, encodeId=56f8195815405, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 06 16:56:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082883, encodeId=2681208288380, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96106, encryptionId=2436961068e, topicName=野生型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 16 01:56:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642734, encodeId=421d1642e3417, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Mon Nov 10 23:56:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895722, encodeId=3b001895e2205, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 18 16:56:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368980, encodeId=206f13689801e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534230, encodeId=e15f1534230af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621221, encodeId=51d21621221b8, content=<a href='/topic/show?id=33fa55081fe' target=_blank style='color:#2F92EE;'>#抗EGFR疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55081, encryptionId=33fa55081fe, topicName=抗EGFR疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10020217711, createdName=guoyibin, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
2014-09-18 一闲

#MET#

50 0
[GetPortalCommentsPageByObjectIdResponse(id=1827225, encodeId=c28c182e2259b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Aug 07 02:56:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958154, encodeId=56f8195815405, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 06 16:56:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082883, encodeId=2681208288380, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96106, encryptionId=2436961068e, topicName=野生型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 16 01:56:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642734, encodeId=421d1642e3417, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Mon Nov 10 23:56:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895722, encodeId=3b001895e2205, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 18 16:56:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368980, encodeId=206f13689801e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534230, encodeId=e15f1534230af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621221, encodeId=51d21621221b8, content=<a href='/topic/show?id=33fa55081fe' target=_blank style='color:#2F92EE;'>#抗EGFR疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55081, encryptionId=33fa55081fe, topicName=抗EGFR疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10020217711, createdName=guoyibin, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
2014-05-07 yinhl1978

#KRAS#

63 0
[GetPortalCommentsPageByObjectIdResponse(id=1827225, encodeId=c28c182e2259b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Aug 07 02:56:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958154, encodeId=56f8195815405, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 06 16:56:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082883, encodeId=2681208288380, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96106, encryptionId=2436961068e, topicName=野生型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 16 01:56:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642734, encodeId=421d1642e3417, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Mon Nov 10 23:56:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895722, encodeId=3b001895e2205, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 18 16:56:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368980, encodeId=206f13689801e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534230, encodeId=e15f1534230af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621221, encodeId=51d21621221b8, content=<a href='/topic/show?id=33fa55081fe' target=_blank style='color:#2F92EE;'>#抗EGFR疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55081, encryptionId=33fa55081fe, topicName=抗EGFR疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10020217711, createdName=guoyibin, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
2014-05-07 liuyiping

#GFR#

53 0
[GetPortalCommentsPageByObjectIdResponse(id=1827225, encodeId=c28c182e2259b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Aug 07 02:56:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958154, encodeId=56f8195815405, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Feb 06 16:56:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082883, encodeId=2681208288380, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96106, encryptionId=2436961068e, topicName=野生型)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Mon Mar 16 01:56:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642734, encodeId=421d1642e3417, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Mon Nov 10 23:56:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895722, encodeId=3b001895e2205, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 18 16:56:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368980, encodeId=206f13689801e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534230, encodeId=e15f1534230af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621221, encodeId=51d21621221b8, content=<a href='/topic/show?id=33fa55081fe' target=_blank style='color:#2F92EE;'>#抗EGFR疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55081, encryptionId=33fa55081fe, topicName=抗EGFR疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10020217711, createdName=guoyibin, createdTime=Wed May 07 07:56:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
2014-05-07 guoyibin

#抗EGFR疗法#

51 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化

CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果

相关资讯

科室

工具

服务